Repros in the News
To receive Press Releases via email, Click Here.
05/12/2008 - 09:59 AM
Repros Therapeutics Inc. Announces That Proellex Shows No Adverse Cardiac Effects In A Pilot Trial
05/09/2008 - 05:23 PM
Repros Therapeutics Inc. Reports First Quarter 2008 Financial Results and Provides Clinical Development Program Overview
05/08/2008 - 02:55 PM
Repros to Report First Quarter 2008 Financial Results on May 9, 2008
03/31/2008 - 11:22 AM
Repros Reports Interim Safety Results From Ongoing One-Year Open Label Study of Proellex(R) in the Treatment of Uterine Fibroids
03/17/2008 - 06:00 AM
Repros Therapeutics Inc. Reports Fourth Quarter and Year End 2007 Financial Results and Provides Clinical Development Program Overview
03/13/2008 - 05:54 PM
Repros to Report Fourth Quarter and Full Year 2007 Financial Results on March 17, 2008
03/07/2008 - 08:00 AM
Repros' Proellex(R) Safety Data Presented At The 13th World Congress of Gynecological Endocrinology
02/22/2008 - 09:15 AM
Repros' IND for the Commencement of Phase III Studies of Proellex(R) in the Treatment of Anemia Associated with Uterine Fibroids is Now Effective
02/08/2008 - 04:20 PM
Repros to Present at the 13th World Congress of Gynecological Endocrinology in Florence, Italy
02/08/2008 - 12:21 PM
Repros Presentation to Be Webcast from The 10th Annual Bio/CEO and Investor Conference 2008
01/31/2008 - 04:18 PM
Repros Announces 2008 Annual Shareholders' Meeting
01/09/2008 - 06:32 PM
Repros and Efficacy Capital Announce Standstill Agreement
01/07/2008 - 05:10 PM
Repros to Present at the 26th Annual JP Morgan Healthcare Conference
12/03/2007 - 06:00 AM
Repros' Lead Product Proellex to Enter Phase 3 for the Treatment of Uterine Fibroid Indications
11/09/2007 - 06:30 AM
Repros Therapeutics Inc. Reports Third Quarter 2007 Financial Results and Provides Clinical Development Update
10/29/2007 - 08:00 AM
Repros Presentation to Be Webcast from CIBC 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
10/17/2007 - 06:31 PM
Repros Provides Update for Regulatory Program Associated with Proellex(R) Development for Uterine Fibroids and Anemia
10/15/2007 - 08:12 PM
Repros Provides Update for Regulatory Program Associated with Androxal(TM) Development
09/12/2007 - 06:00 AM
Repros Therapeutics Announces U.S. IND for the Study of Proellex(R) in the Treatment of Endometriosis Has Become Effective
08/27/2007 - 12:30 PM
Repros Provides Update for Regulatory Program Associated with Androxal Development
08/08/2007 - 06:00 AM
Repros Therapeutics Inc. Reports Second Quarter 2007 Financial Results
07/25/2007 - 06:31 PM
Repros Reports That Patients Exposed to Proellex For Up To Six Months Demonstrated A Benign Endometrium Based On Biopsy
07/05/2007 - 06:30 AM
Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
06/11/2007 - 06:31 PM
Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
06/05/2007 - 06:00 AM
Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax